GE HealthCare Technologies declares $0.035 Q2 2026 dividend

GE HealthCare Technologies Inc. has declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2026. The dividend is payable on August 14, 2026, to shareholders of record as of July 24, 2026. This announcement provides shareholders with a return on their investment for the upcoming quarter.

Dividend Details

The Board of Directors of GE HealthCare Technologies Inc. approved the dividend, marking the company's continued commitment to returning value to its shareholders. The payment schedule ensures that investors holding the stock on the record date will receive the dividend.

Dividend Component	Details
Dividend per share	$0.035
Payable date	August 14, 2026
Record date	July 24, 2026
Quarter	Q2 2026

Company Overview

GE HealthCare is a global healthcare solutions provider offering advanced medical technology, pharmaceutical diagnostics, and AI, cloud, and software solutions. The company operates across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments. With a $20.6 billion business and approximately 54,000 colleagues, GE HealthCare aims to deliver personalized and precise patient care. The company is recognized among the 2026 Fortune World’s Most Admired Companies.

GE HealthCare today announced Allia platform upgrade pathways designed to help customers modernize select legacy Innova and Discovery Image Guiding Solutions (IGS) systems. These pathways provide access to Allia technologies and workflows that support efficiency and procedural decision-making while helping preserve existing infrastructure, avoid major construction work, extend interventional room lifetime, and minimize disruption to clinical operations.

As procedural complexity and patient volumes grow and installed systems age, healthcare providers are looking for flexible ways to modernize interventional environments. According to the European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry (COCIR), one-third of interventional X-ray systems in Europe are more than 10 years old, highlighting the importance of technology renewal planning.

Upgrade Capabilities

The upgrade pathways can help customers extend the value of existing systems through workflow enhancements, expanded interoperability capabilities and access to Allia innovations. Depending on system configuration, market availability and applicable regulatory requirements, upgrade options may provide access to capabilities and to third party solutions.

Technology	Description
CleaRecon DL	AI-enabled deep learning reconstruction technology designed to support CBCT image interpretation confidence by reducing streak artifacts.
3DStent	Intraprocedural tool for 3D visualization of the coronary stent designed to remove major stent imaging barriers.
OmnifyXR Interventional Suite	Augmented reality guidance solution designed to support workflow efficiency and ergonomics.
Embo ASSIST AI	Augmented guidance solution designed to optimize embolization strategies and streamline clinical workflow.
Medis Quantitative Flow Ratio	Software solution designed to assess coronary physiology in patients with coronary artery disease.
AVVIGO+ intravascular imaging platform	Multimodality guidance platform that enhances the IVUS and physiology experience.

Strategic Value

"Interventional care continues to evolve rapidly, and health systems are looking for technology strategies that balance innovation, operational continuity and long-term value," said Jyoti Gera, CEO, CardioVascular and Interventional Solutions, Advanced Imaging Solutions, GE HealthCare. "These Allia upgrade pathways reflect our commitment to helping customers modernize on their own terms by extending the capabilities of existing systems while providing access to the latest Allia innovations and AI-enabled technologies in a less disruptive, more sustainable way."

GE HealthCare also provides Tube Watch and/or OnWatch Predict service options on all upgraded systems. These options help customers proactively manage system performance and maintenance by providing an AI-powered estimated lead time to failure, supporting efforts to reduce unplanned downtime. These upgrade pathways are available in the U.S. and other countries where Allia IGS and Allia IGS Pulse systems are available for sale.